1/2

ABOUT TYPE 2 DIABETES

A GROWING GLOBAL HEALTH CRISIS

More than 350MM people globally living with type 2 diabetes
Diabetes is the leading cause of kidney failure, lower-limb amputations & blindness in adults
Average annual medical expenditure > 2.3x higher for diabetics

MAJORITY OF PATIENTS ARE NOT ACHIEVING TREATMENT GOALS

> $35Bn annual market for type 2 diabetes medical therapies
• Average type 2 patient is on more than
6 prescription medications
Fewer than 50% of patients achieve target HbA1c

CHALLENGES TO MAINTAINING OPTIMAL MEDICAL THERAPY

Polypharmacy result in regular tolerability issues for more than 70% of patients
Clinical inertia delays therapy progression in 50+% of patients
Only ~40% of patients are compliant with medical therapy after 12-24 months

 

A NEW PATH TO METABOLIC HEALTH

The small intestine plays a key role in regulating metabolic processes and insulin resistance.  Studies have shown that up to 90% of patients who undergo bariatric surgery with duodenal exclusion achieve improved insulin resistance and glycemic control.

Digma aims to harness the power of the duodenum to empower patients and physicians with safe, simple and effective new therapies for type 2 diabetes that enable them to live longer, healthier and happier lives.

We are developing a minimally invasive therapy, Endoscopic Glycemic Management (EGM), that aims to restore the body’s natural ability to control blood glucose levels.  The treatment targets the duodenal submucosa which is central to nutrient sensing and metabolic signaling.


Our product consists of a console and a single-use catheter that is compatible with the working channel of standard gastrointestinal endoscopes. The EGM procedure is being developed so that it can be performed in a standard GI endoscopy suite without requiring additional imaging equipment.  Our goal is to provide patients with durable improvement in glycemic control with minimal side effects and without requiring additional daily medical therapy.


The EGM procedure  is currently being evaluated in clinical studies.  To learn more about our clinical program, please contact us here.

 

LEADERSHIP TEAM

JAMES MCNALLY

President and CEO

BRIAN L. LEVY, MD, FACE

Chief Medical Officer

YANIV KIRMA

COO and Site Manager

ILAN BEN-OREN

Co-founder and CTO

HILA DAGAN, PhD

Head of Regulatory Affairs

 

BOARD OF DIRECTORS

Scott Huennekens

Executive Chairman, Digma Medical

Mori Arkin

Arkin Holdings

Ilan Ben-Oren

Co-founder & CTO, Digma Medical

Eyal Dior

Tal Capital

Uri Geiger

AccelMed

Anat Tsour Segal

CBG Ventures

James McNally

President & CEO, Digma Medical

Irit Yaniv, MD

AccelMed & Co-founder, Digma Medical

 

INVESTORS

Digma Medical is a privately held company backed by these leading venture capital firms

Accelmed
Peregrine
 
 

The Digma system is for investigational use only and is not available for sale in any geography.
©2020 by Digma Medical